Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar plus Icotinib in EGFR-positive Advanced NSCLC
NCT03008109Phase 3Unknown
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
A Phase 3 trial of endostar in non-small cell lung cancer (NSCLC). Status: unknown.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03008109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03008109.